secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001558370-24-012055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Q2 operating loss $11.9M; AP-PA02 Phase 2 enrollment complete, topline H2 2024
--------------------------------------------------------------------------------

- Q2 2024 operating loss $11.9M vs $9.6M in Q2 2023; R&D $8.5M, G&A $3.4M.
- Cash and equivalents $26.4M as of June 30, 2024, up from $13.5M at Dec 31, 2023.
- Completed enrollment in Phase 2 Tailwind study of inhaled AP-PA02; last patient visit Aug 7, topline data expected H2 2024.
- Received $5.25M non-dilutive DoD grant for AP-SA02 diSArm Phase 2a study.
- Built out cGMP manufacturing facility with five clean rooms, including fill-and-finish suite.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837024012055/0001558370-24-012055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837024012055/armp-20240813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer